SIFI Acquires Laboratoire Gifrer Barbezat’s Dacudoses and Novoptine for $6.7M in France

 SIFI Acquires Laboratoire Gifrer Barbezat’s Dacudoses and Novoptine for $6.7M in France

SIFI Acquires Laboratoire Gifrer Barbezat’s Dacudoses and Novoptine for $6.7M in France

Shots:

  • SIFI acquires two leading ophthalmic antiseptic candidates of Gifrer Barbezat for a total value of $6.7M and will be available in the French market from Jan’2020 through its subsidiary SIFI France
  • The focus of the acquisition is to expand SIFI’s ophthalmic portfolio with the addition of Grifer’s Dacudoses & Novoptine products and to accelerate the expansion of SIFI’s footprints in the French market
  • Dacudoses is used as an eyewash in case of conjunctivitis whereas Novoptine is an OTC antiseptic collyrium indicated for the treatment of eye infections and conjunctivitis

Click here to read full press release/ article | Ref: SIFI | Image: Tooteko

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post